Olema制药公司首席执行官和董事出售股票,股票价格下跌至8.41美元。 Olema Pharmaceuticals' CEO and director sold shares, coinciding with a stock price drop to $8.41.

Olema制药公司(NASDAQ:OLMA)内幕人士,包括CEO Sean Bohen和Cyrus Harmon董事,最近出售股票,减少了股票所有权。 Olema Pharmaceuticals (NASDAQ:OLMA) insiders, including CEO Sean Bohen and Director Cyrus Harmon, recently sold shares, reducing their stock ownership. 12月11日公司股票价格下跌1.23美元至8.41美元。 The company's stock price fell $1.23 to $8.41 on December 11th. Olema正在研制OP-1250,治疗某些类型的乳腺癌,目前处于临床试验第三阶段。 Olema is developing OP-1250, a treatment for certain types of breast cancer, and is in Phase 3 clinical trials. 机构投资者拥有91.78%的股票,HC Wainwright给予它“买”评级和30.00美元目标价格。 Institutional investors own 91.78% of the stock, with HC Wainwright giving it a "buy" rating and a $30.00 target price.